Top

Published in:

01-03-2021 | Stroke | Review

Targeting blood pressure for stroke prevention: current evidence and unanswered questions

Author: Yannick Béjot

Published in: Journal of Neurology | Issue 3/2021

Abstract

High blood pressure (BP) is the leading modifiable risk factor of stroke worldwide. Although randomized clinical trials have demonstrated the beneficial effect of BP reduction on stroke risk, there are still insufficiently explored issues concerning the optimal personalized management of BP in stroke patients in terms of thresholds to be achieved and drug classes to be prescribed. Few data are available about BP control in specific clinical contexts such as in older patients, in various stroke subtypes, or in association with co-morbidities such as diabetes. In addition, although drug trials based their conclusions on achieved mean BP values, recent findings indicate that aspects such as circadian variations of BP and BP variability should be taken into account as well. This article aims to highlight current knowledge about BP control in stroke prevention and to provide new perspectives to be addressed in future studies so as to guide clinicians in their day-to-day practice.

Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al (2017) Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990–2015. JAMA 317:165–182PubMed

Marshall IJ, Wang Y, McKevitt C, Rudd AG, Wolfe CD (2013) Trends in risk factor prevalence and management before first stroke: data from the South London Stroke Register 1995–2011. Stroke 44:1809–1816PubMed

Anderson CS, Carter KN, Hackett ML, Feigin V, Barber PA, Broad JB et al (2005) Trends in stroke incidence in Auckland, New Zealand, during 1981 to 2003. Stroke 36:2087–2093PubMed

Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM et al (2004) Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363:1925–1933PubMed

Heuschmann PU, Di Carlo A, Béjot Y, Rastenyte D, Ryglewicz D, Sarti C et al (2009) Incidence of stroke in Europe at the beginning of the 21st century. Stroke 40:1557–1563PubMed

Béjot Y, Daubail B, Giroud M (2016) Epidemiology of stroke and transient ischemic attacks: current knowledge and perspectives. Rev Neurol (Paris) 172:59–68

Béjot Y, Troisgros O, Gremeaux V, Lucas B, Jacquin A, Khoumri C et al (2012) Poststroke disposition and associated factors in a population-based study: the Dijon Stroke Registry. Stroke 43:2071–2077PubMed

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913PubMed

O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H et al (2016) Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 388:761–775PubMed

10.

Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S et al (2016) Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet Neurol 15:913–924PubMed

11.

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967PubMed

12.

PROGRESS collaborative group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041

13.

Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA et al (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225–1237PubMedPubMedCentral

14.

Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA et al (2013) Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382:507–515PubMed

15.

The Dutch TIA Trial Study Group (1993) Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 24:543–548

16.

PATS Collaborating Group (1995) Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 108:710–717

17.

Eriksson S, Olofsson BO, Wester PO, for the TEST study group (1995) Atenolol in secondary prevention after stroke. Cerebrovasc Dis 5:21–25

18.

Liu LS, Gong LS, Wang W, Blood Pressure Lowering to Prevent Recurrent Stroke Study Group (2005) Effects of blood pressure lowering treatment on stroke recurrence in patients with cerebrovascular diseases-a large-scale, randomized, placebo controlled trial. Zhonghua Xin Xue Guan Bing Za Zhi 33:613–617PubMed

19.

Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S et al (2004) Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 35:116–121PubMed

20.

Obviagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R et al (2011) Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 306:2137–2144

21.

Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS et al (2016) Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial. Hypertension 67:63–69PubMed

22.

Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A et al (2017) Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension 69:171–179PubMed

23.

Carter AB (1970) Hypotensive therapy in stroke survivors. Lancet 1:485–489PubMed

24.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153PubMed

25.

Hypertension-Stroke Cooperative Study Group (1974) Effect of antihypertensive treatment on stroke recurrence. JAMA 229:409–418

26.

Martí Massó JF, Lozano R (1990) Nicardipine in the prevention of cerebral infarction. Clin Ther 12:344–351PubMed

27.

Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J et al (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218–1226PubMed

28.

Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U et al (2016) Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (prevention after stroke-blood pressure) randomised controlled trial. BMJ 352:i708PubMedPubMedCentral

29.

Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al (2003) The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21:875–886PubMed

30.

Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS et al (2014) Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 383:333–341PubMed

31.

Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF et al (2017) Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology 88:379–385PubMedPubMedCentral

32.

Giroud M, Delpont B, Daubail B, Blanc C, Durier J, Giroud M, Béjot Y (2017) Temporal trends in sex differences with regard to stroke incidence: the Dijon Stroke Registry (1987–2012). Stroke 48:846–849PubMed

33.

Béjot Y, Bailly H, Graber M, Garnier L, Laville A, Dubourget L et al (2019) Impact of the ageing population on the burden of stroke: the Dijon Stroke Registry. Neuroepidemiology 52:78–85PubMed

34.

White CL, Szychowski JM, Pergola PE, Field TS, Talbert R, Lau H et al (2015) Can blood pressure be lowered safely in older adults with lacunar stroke? The secondary prevention of small subcortical strokes study experience. J Am Geriatr Soc 63:722–729PubMedPubMedCentral

35.

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898PubMed

36.

Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116

37.

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA 315:2673–2682PubMedPubMedCentral

38.

Cushman C, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585PubMed

39.

Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC et al (2014) Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37:1721–1728PubMedPubMedCentral

40.

Bangalore Kumar S, Lobach I, Messerli FH (2011) Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 123:2799–2810PubMed

41.

Brunström M, Carlberg B (2016) Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 352:i717PubMedPubMedCentral

42.

Rothwell PM (2010) Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 375:938–948PubMed

43.

Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B et al (2010) Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375:895–905PubMed

44.

Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Poulter NR et al (2010) Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9:469–480PubMed

45.

Webb AJ, Fischer U, Mehta Z, Rothwell PM (2010) Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375:906–915PubMed

46.

Melhum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM et al (2018) Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J 39:2243–2251

47.

Yano Y, Kario K (2012) Nocturnal blood pressure, morning blood pressure surge, and cerebrovascular events. Curr Hypertens Rep 14:219–227PubMed

48.

Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K (2001) Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 38:852–857PubMed

49.

Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al (2003) Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 107:1401–1406PubMed

50.

Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S et al (2010) Morning and evening home blood pressure and risks of incident stroke and coronary artery disease in the Japanese general practice population: the Japan Morning Surge-Home Blood Pressure Study. Hypertension 68:54–61

51.

Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y et al (2014) Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension 64:989–996PubMed

52.

Björklund K, Lind L, Zethelius B, Andrén B, Lithell H (2003) Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 107:1297–1302PubMed

53.

Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM et al (2005) Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 18:1422–1428PubMed

Title: Targeting blood pressure for stroke prevention: current evidence and unanswered questions
Author: Yannick Béjot
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keywords: Stroke
Hypertension
Hypertension
Published in: Journal of Neurology / Issue 3/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09443-5

2024 ASCO Annual Meeting

Springer Medicine

Targeting blood pressure for stroke prevention: current evidence and unanswered questions

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?

Manifold learning for amyotrophic lateral sclerosis functional loss assessment

Unusual electrophysiological findings in a Chinese ALS 4 family with SETX-L389S mutation: a three-year follow-up

Better quality of life and less caregiver strain in young-onset Parkinson’s disease: a multicentre retrospective cohort study

Cardiogenic vertigo: characteristics and proposed diagnostic criteria

Causality in COVID-19-associated stroke: a uniform case definition for use in clinical research